Early strategies targeting CSPG4 utilized the development of anti-idiotypic antibodies (anti-id), which target the binding sites of other anti-CSPG4 antibodies, essentially mimicking the tumor antigen’s binding site on the antibody, and thus aiming to serve as immunogens or vaccines (91, 92). The gene discussed is CSPG4; the disease is neoplasm.